The Observation Of Clinical Effect For Yiganhuayu Decoction In The Treatment Of Hepatitis B Hepatic Fibrosis(Liver Deficiency And Blood Stasis Type)

Objective:To study the efficacy and safety of Yiganhuayu Decoction in the treatment of hepatitis B fibrosis caused by liver deficiency and blood stasis,and to provide theoretical support for the development of new TCM treatment methodsMethods:In accord with the standard of 86 cases of patients,86 cases were randomly divided into treatment group and control group,treatment group given Yiganhuayu Decoction and entecavir treatment,control group given Compound Biejia Ruangan Tablets and entecavir treatment for 12 weeks,record the patient’s symptoms and signs before and after the treatment respectively Liver function:(ALT,AST),liver fiber four:(PⅢNP,HA,LN,CIV),values of LSM(Fibro Scan technology)colour doppler ultrasound(portal vein width)results and related safety index application SPSS25.0 analysis data.Results:1.The clinical effective rate of the Yiganhuayu Decoction group was 85.00%,The effective rate of the control group was 65.85%(P<0.05).The difference between the two groups was statistically significant.2.TCM syndrome scores: After treatment,the TCM syndrome scores of the two groups were lower than before(P<0.05),and the score of the Yiganhuayu Decoction group was lower than that of the control group,it showed that P<0.05 when comparing the differences between the two groups.3.The curative effect of TCM syndrome:The respective curative effect of TCM syndromes in the Yiganhuayu Decoction group and the control group was92.5% and 68.3%,and the difference was statistically significant(P<0.05).4.Liver function: After treatment,ALT and AST in both groups were improved(P<0.05),and the group of Yiganhuayu Decoction was better than control group when comparing the liver function differences between the two groups(P<0.05).5.Four hepatic fibrosis:After treatment,Four hepatic fibrosis of the two groups were lower than before(P<0.05).the Yiganhuayu Decoction group of PⅢNP 、 HA 、 LN was lower than control group when comparing Four hepatic fibrosis differences between the two groups(P<0.05).But the effective of CIV of Yiganhuayu Decoction group is equivalent to the control group(P>0.05).6.LSM:The LSM of both groups was lower than before treatment(P<0.05),and the LSM of Yiganhuayu Decoction group was lower than that of the control group,and the difference between the two groups was statistically significant(P<0.05).7.Color doppler ultrasound: After treatment,portalvein width of the two groups were improved(P<0.05),but the difference between the two groups was not significant(P>0.05).8.Safety: The patient’s safety indicators were not significantly abnormal before and after treatment;during the observation period,the patients had no significant adverse reactions.Conclusions:1.Yiganhuayu Decoction can improve the TCM syndrome score,liver function,LSM value,Four hepatic fibrosis(PⅢNP、HA、LN)of patients with liver deficiency and blood stasis type hepatitis B fibrosis.2.Yiganhuayu Decoction is equivalent to Compound Biejia Ruangan tablets alone in improving portal vein width,and Serum type IV collagen(CIV)in patients with liver deficiency and blood stasis type hepatitis B fibrosis.3.In clinical application,Yiganhuayu Decoction has high safety.